Verve Therapeutics gene-edited therapy sparks influencer debates on cholesterol reduction and cardiovascular health

Verve Therapeutics’ investigational medicine, VERVE-101, has reportedly shown a remarkable 55% reduction in bad cholesterol levels during early clinical trials. The single-dose, gene-edited therapy holds immense promise for those with familial hypercholesterolemia, addressing a critical need in heart health. This has triggered a dramatic rise in discussions over the preceding week around “Gene Editing” on social media platform “X”, reveals the Social Media Analytics Platform of GlobalData, a leading data and analytics company.

Smitarani Tripathy, Social Media Analyst at GlobalData, comments: “The response from influencers to Verve Therapeutics’ gene-editing breakthrough is diverse. While some hail it as a groundbreaking development, acknowledging its impressive in vivo liver gene editing and potential for lasting cholesterol reduction, others advocate for caution. Safety concerns and the risk of off-target effects prompt a call for validation in other diseases before wholehearted support.”

Below are a few popular influencer opinions captured by GlobalData’s Social Media Analytics Platform:

  1. Daniel Kraft, Founder of NextMed.Health and Digital.Health with near 60K followers, says that the trial shows in-vivo gene editing treatment significantly lowers cholesterol permanently in 10 patients, offering a potential single-dose solution for heart disease prevention.
  2. Stuart Smyth, Sustainability Chair at USask with 10K followers, says that it isn’t a minor advancement; it’s a significant leap into uncharted territory, by which cholesterol can be reduced and decrease the occurrences of heart disease.
  3. Katalin Susztak, a Physician Scientist at University of Pennsylvania with 5K followers, stated this as potential medical breakthrough and a new era in medicine.
  4. Pearl Freier, Founder of Cambridge BioPartners, Inc with more than 7K followers, was excited that that a sole gene editing treatment could permanently lower cholesterol in high-risk heart disease patients.
  5. Eric Topol, Cardiologist with 689K followers, tweeted that though there is potential for cholesterol reduction, it also includes concerns for safety, alternative therapies, off-target editing, and magnitude of effect.
  6. Venky Murthy, Associate Chief of Cardiology for Translational Research & Innovation, University of Michigan with 21K followers, opine that it requires validation in other diseases first. It might be a good time to shift focus from gene editing of PCSK9 for the time being.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we're very happy to help.

DECODED Your daily industry news round-up

This site is registered on as a development site.